



## Capecitabine Accord

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
IA/0043	A.7 - Administrative change - Deletion of manufacturing sites	07/12/2021		SmPC and PL	
IB/0042	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference	06/12/2021		SmPC and PL	

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
PSUSA/531/2 02104	Periodic Safety Update EU Single assessment - capecitabine	02/12/2021	n/a		PRAC Recommendation - maintenance
IAIN/0040/G	<p>This was an application for a group of variations.</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the</p>	26/03/2021		Annex II and PL	

	<p>relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p>				
IAIN/0039	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	08/03/2021		SmPC and PL	
A31/0032	<p>Pursuant to Article 31 of Directive 2001/83/EC, France requested on 13 March 2019 the opinion of the European Medicines Agency to assess the need to take action at EU level regarding the detection of DPD deficient patients (especially through genotyping and/or phenotyping) in patients treated with fluorouracil and related substances (capecitabine, tegafur and flucytosine). The Agency was requested to assess the impact thereof on the benefit-risk balance of fluorouracil and related substances containing products and to give its opinion on whether the marketing authorisation of these products should be maintained, varied, suspended or revoked.</p>	30/04/2020	03/07/2020	SmPC and PL	Please refer to the assessment report: Capecitabine Accord EMEA/H/A-31/1481/C/002386/0032

IB/0037	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	05/06/2020	17/07/2020	SmPC and PL	
IAIN/0038	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	13/05/2020	n/a		
IB/0036	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	11/10/2019	03/07/2020	SmPC and PL	
IAIN/0035	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	17/09/2019	n/a		
IAIN/0034	B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)	22/07/2019	n/a		
IA/0033/G	This was an application for a group of variations.  B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the	15/05/2019	n/a		

	relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer				
PSUSA/531/201804	Periodic Safety Update EU Single assessment - capecitabine	31/01/2019	02/04/2019	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/531/201804.
IA/0031	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	05/03/2019	n/a		
T/0030	Transfer of Marketing Authorisation	01/02/2019	25/02/2019	SmPC, Labelling and PL	
IA/0029	B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size	18/12/2018	n/a		
IB/0027	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO	12/10/2018	25/02/2019	SmPC	

	new additional data is required to be submitted by the MAH				
IAIN/0028/G	<p>This was an application for a group of variations.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p>	21/09/2018	25/02/2019	Annex II and PL	
IAIN/0025	B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)	20/07/2017	n/a		
IAIN/0024	B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from	24/01/2017	n/a		

	an already approved manufacturer				
R/0021	Renewal of the marketing authorisation.	10/11/2016	09/01/2017	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Capecitabine Accord in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IA/0022	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	14/09/2016	n/a		
IB/0023	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	31/08/2016	09/01/2017	SmPC, Labelling and PL	
IAIN/0020	B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer	21/07/2016	n/a		
IAIN/0019	B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS	29/03/2016	n/a		
IB/0018	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following	07/03/2016	02/06/2016	SmPC, Annex	

	assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH			II and PL	
IAIN/0016/G	This was an application for a group of variations.  B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size  B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS	29/02/2016	n/a		
IA/0017	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	22/02/2016	n/a		
PSUSA/531/201504	Periodic Safety Update EU Single assessment - capecitabine	03/12/2015	n/a		PRAC Recommendation - maintenance
IA/0014	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	17/07/2015	n/a		
IB/0013	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference	04/06/2015	02/06/2016	SmPC and PL	



	product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IB/0012	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	26/06/2014	n/a		
IB/0011/G	<p>This was an application for a group of variations.</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p>	04/04/2014	13/04/2015	SmPC, Annex II and PL	

	new additional data is required to be submitted by the MAH				
IB/0010	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	10/02/2014	n/a		
IA/0009	B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size	20/12/2013	n/a		
IA/0008	B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size	31/10/2013	n/a		
IB/0006	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	26/09/2013	20/02/2014	SmPC, Annex II and PL	
IAIN/0007	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	30/08/2013	n/a		
IB/0005/G	This was an application for a group of variations.  B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold	18/07/2013	n/a		

	<p>increase compared to the currently approved batch size</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p>				
IB/0004	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	18/04/2013	20/02/2014	SmPC	
N/0001	<p>To combine the package leaflets of Capecitabine Accord 150mg, 300mg and 500mg.</p> <p>Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)</p>	08/04/2013	20/02/2014	PL	
IAIN/0003/G	<p>This was an application for a group of variations.</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished</p>	26/03/2013	20/02/2014	SmPC, Labelling and PL	

<p>product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p> <p>B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes</p>				
--	--	--	--	--

IB/0002

C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH

06/03/2013

20/02/2014

SmPC, Annex II and PL